This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chen, Z.-P. Articles by Panasci, L. C. Search for Related Content PubMed PubMed Citation Articles by Chen, Z.-P. Articles by Panasci, L. C.

Extraneuronal Monoamine Transporter Expression and DNA Repair Vis-à-Vis 2-Chloroethyl-3-sarcosinamide-1-nitrosourea Cytotoxicity in Human Tumor Cell Lines¹

Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Quebec, Canada H3T 1E2 [Z. P. C., G. M., L. C. P.], and Department of Molecular Pharmacology, St. Jude Children’s Research Hospital, Memphis, Tennessee 38105-2794 [J. R., T. P. B.]

We previously found that 2-chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU), a new chloroethylnitrosourea analogue presently in phase I clinical trials, is a selective cytotoxin that enters cells via the extraneuronal transporter for monoamine transmitters (EMT). In this study, we assessed whether EMT expression correlates with SarCNU cytotoxicity by determining EMT expression in 23 human tumor cell lines with reverse-transcription PCR. Western blot analysis was used to measure protein levels of the DNA repair genes, O⁶-methylguanine-DNA methyltransferase (MGMT), and excision repair cross-complementing rodent repair deficiency gene 2 (ERCC2). SarCNU cytotoxicity was determined by the sulforhodamine B colorimetric anticancer-drug screening assay and correlated with gene expression. Almost all of the cell lines screened were positive for EMT expression. However, seven cell lines (MGR-1, MGR-2, T98-G, SKI-1, SKNSH, 297, and GBM) expressed low levels of EMT. Although there was no linear correlation between SarCNU cytotoxicity and EMT expression, SarCNU cytotoxicity significantly correlated with ERCC2 protein levels, and MGMT-rich (Mer⁺) cell lines (MGMT protein level >0.1) were more resistant to SarCNU than MGMT-poor (Mer^-) cell lines (MGMT protein level <0.1). Moreover, multiple regression analysis indicated that the best correlation with SarCNU cytotoxicity was attainable with EMT plus MGMT and ERCC2 expression. This study suggests that in human tumor cell lines both EMT and DNA repair factors, specifically, MGMT and ERCC2, are important determinants of SarCNU activity. Because EMT is expressed in a wide variety of human tumors, SarCNU should be a more widely effective alternative chemotherapeutic agent.

This article has been cited by other articles:

				J. Jiang, X. Chen, J. Shen, Y. Wei, T. Wu, Y. Yang, H. Wang, H. Zong, J. Yang, S. Zhang, et al. beta1,4-Galactosyltransferase V Functions as a Positive Growth Regulator in Glioma J. Biol. Chem., April 7, 2006; 281(14): 9482 - 9489. [Abstract] [Full Text] [PDF]

				F. Giles, D. Thomas, G. Garcia-Manero, S. Faderl, J. Cortes, S. Verstovsek, A. Ferrajoli, S. Jeha, M. Beran, C. Koller, et al. A Phase I and Pharmacokinetic Study of VNP40101M, a Novel Sulfonylhydrazine Alkylating Agent, in Patients with Refractory Leukemia Clin. Cancer Res., May 1, 2004; 10(9): 2908 - 2917. [Abstract] [Full Text] [PDF]

				L. Panasci, S.F. Stinson, D. Melnychuk, V. Sandor, W.H. Miller Jr, G. Batist, F. Patenaude, N. Bangash, L. Panarello, M. Alaoui-Jamali, et al. SarCNU, a Nitrosourea Analog on a Day 1, 5, and 9 Oral Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Tumors J. Clin. Oncol., January 15, 2003; 21(2): 232 - 240. [Abstract] [Full Text] [PDF]

				Z.-P. Chen, Z.-M. Wang, C. A. Carter, M. C. Alley, G. Mohr, and L. C. Panasci Both Extraneuronal Monoamine Transporter and O6-Methylguanine-DNA Methyltransferase Expression Influence the Antitumor Efficacy of 2-Chloroethyl-3-sarcosinamide- 1-nitrosourea in Human Tumor Xenografts J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 712 - 715. [Abstract] [Full Text]